DT03 Rec'd PCT/PTO 0 1 SEP 2004

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCO OFFICE (MODIFIED)	ATTORNEY'S DOCKET NUMBER						
TRANSMITTAL LETTER TO THE UNITED STATES		X-15654 U.S. APPLICAT. O. (if known, see 37 C.F.R. 1.5)					
DESIGNATED/ELECTED OFFICE (DO/EO/US)		10/506459					
CONCERNING A FILING UNDER 35 U.S.C. 371							
INTERNATIONAL APPLICATION NO. PCT/US03/05050	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
1 C 17 0503/05050	04 March 2003 (04.03.2003) 05 March 2002 (05.03.200						
TITLE OF INVENTION: PURINE DERIVATIVES AS KINASE INHIBITORS							
APPLICANT(S) FOR DO/EO/US: Joshua Ryan CLAYTON, Clive Gideon DIEFENBACHER, Thomas Albert ENGLER, Kelly							
Wayne FURNESS, James Robert HENRY, Sushant MALHOTRA, Angela Lynn MARQUART, Johnathan Alexander MCLEAN, David MENDEL, Timothy Paul BURKHOLDER, Yihong LI, Jon Kevin REEL, Brian Raymond BERRIDGE, Charles Edward RUEGG, John Morris SULLIVAN							
Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:							
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2. This is a SECOND or SUBSEQUEN	2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3 This express request to begin national	examination procedures (35 U.S.	C. 371(f)) at any time rather than delay					
examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).							
4. X A proper Demand for International Pr	eliminary Examination was made	by the 19th month from the earliest claimed					
priority date.							
5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
a. is transmitted herewith (requ	a is transmitted herewith (required only if not transmitted by the International Bureau).						
b. has been transmitted by the International Bureau.							
c. X is not required, as the applic	eation was filed in the United Stat	es Receiving Office (RO/US).					
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).							
7. X Amendments to the claims of the Inter	national Application under PCT	Article 19 (35 U.S.C. 371 (c)(3))					
a. are transmitted herewith (required only if not transmitted by the International Bureau).							
b. have been transmitted by the International Bureau.							
c: have not been made; however, the time limit for making such amendments has NOT expired.							
d. X have not been made and will not be made.							
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.							
11. X A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an							
English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 12. to 18. below concern document(s) or information included:							
12. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
Assignment has been recorded at reel <u>013034</u> , frame <u>0074</u> .							
A FIRST preliminary amendment.							
A SECOND or SUBSEQUENT preliminary amendment.							
· · · · · · · · · · · · · · · · · · ·	A Sequence Listing, 1.821 Statement, and diskette.						
X A power of attorney.							
18. X Other items or information:	8. X Other items or information:						
Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US03/05050, filed 4 March 2003, which, claims the benefit, under 35 USC 119(e), of US provisional application 60/362,245, filed 5 March 2002."							

I.S. APPLICATION NO. (if known, see 37 C.F.P. INTERNATIONAL APPLICATION NO. (INTERNATIONAL APPLICATION NO. (INTERNATION						
10	150645	PCT/US03/05050		X-15654		
	g fees are submitted:			CALCULATIONS	PTO USE ONLY	
BASIC NATION	NAL FEE (37 CFR 1	.492(a)(1)-(5)):				
Neither internation	onal preliminary exam					
	search fee (37 CFR 1		•			
and International	Search Report not pro					
	iminary examination Search Report prepar					
	iminary examination ch fee (37 CFR 1.445	·				
	iminary examination not satisfy provisions					
International prol	iminant avamination	foo moid to USDTO (27 CI	DE			
		fee paid to USPTO (37 Clons of PCT Article 33(2)-(
1.702) and an on	mis satisfied provisio	7 THOU 33(2)	1)			
		PRIATE BASIC FE				
		or declaration later than	2030	\$		
months from the earlie CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	 	<u> </u>	
Total claims	14-20=		X \$18.00	\$		
Independent claims	1-3=	: 0	X \$86.00	· ·		
MULTIPLE DEPEND	ENT CLAIM(S) (if a	upplicable)	+ \$290.00	ΙΨ		
TOTAL OF ABOVE CALCULATIONS =			\$270.00			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity			\$			
Statement must also be				Ψ		
SUBTOTAL =			\$290.00			
Processing fee of \$130.00 for furnishing English translation later than 2030 months from the earliest claimed priority date (37 CFR 1.492(f)). +			\$			
TOTAL NATIONAL FEE =			\$			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be			\$			
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property						
TOTAL FEES ENCLOSED =			\$1,210.00			
TOTAL TILLS DIVELOSED =			Amount to be	\$		
				refunded	Φ	
				charged	\$,	
a. A check in the amount of \$ to cover the above fees is enclosed. b. X Please charge my Deposit Account No. 05-0840 in the amount of \$1,210.00 to cover the above fees. A duplicate						
copy of this sheet is enclosed. c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any						
overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive						
(37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPO ELI LILLY AND COM		Meth.	Ehr-			
PATENT DIVISION SIGNATURE						
P.O. BOX 6288 INDJANAPOLJS, INDIANA 46206-6288 Robert D. TITUS						
September 1, 2004 NAME			25885			
Date	Date (317) 277-3729			PATENT TRADEMA	RK OFFICE	
40,206		TELEPHONE NUMBER				
REGISTRATION NUM	RFR I		i			

DT03 Rec'd PCT/PTO 0, 1 SEP 2004

IN THE TITED STATES RECEIVING OFFICE (SECO)

Applicant(s): CLAYTON, Joshua Ryan

DIEFENBACHER, Clive Gideon

ENGLER, Thomas Albert
FURNESS, Kelly Wayne
HENRY, James Robert
MALHOTRA, Sushant

MARQUART, Angela Lynn

MCLEAN, Johnathan Alexander

MENDEL, David

BURKHOLDER, Timothy Paul

LI, Yihong

REEL, Jon Kevin

BERRIDGE, Brian Raymond RUEGG, Charles Edward SULLIVAN, John Morris

International Application No.:

PCT/\u00e4S03/05050

Filed:

4 March 2003 (04.03.03)

Invention:

PURINE DERIVATIVES AS KINASE INHIBITORS

Lilly Reference:

X-15654

Earliest Priority Date:

5 March 2002

Certificate Under 37 C.F.R. § 1.10

Attention: RO/US
Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir/Madam:	

832951865

"Express Mail" mailing label n imber:

EL 832896395 US

Date of Deposit: \mathcal{O}

2004

I hereby certify that this pape for fee is being deposited with the United States

Postal Service "Express May Post Office to Addressee" service under

37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Oueen Thomas

(Typed or printed name of person mailing paper)

(Signature of person mailing paper or fee)